NEU 0.15% $13.13 neuren pharmaceuticals limited

Mass Exodus, page-50

  1. 6,196 Posts.
    lightbulb Created with Sketch. 1647
    I find it incredible that we are below the SP (without a great deal of dilution in between) that we were post results of the P2 pediatric trial.

    Think of the progress (without any regress) since then. The Lanstead funding, FDA approval, under favourable conditions, for the P3 and now a deal to fund that trial, with significant upside if successful plus funds to pursue 2591 development.

    Crazy.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.